Tag: AstraZeneca

<img width="1200" height="675" alt="artificial intelligence investment algorithms" fetchpriority="high" sizes="(max-width: 1200px) 100vw, 1200px" srcset="https://cdn-dfoll.nitrocdn.com/tSUsPcuDMaCDjkKGRxswpkeBalYirhyT/assets/images/optimized/rev-6b6fbab/www.fool.co.uk/wp-content/uploads/2023/06/ai-1200x675.jpg 1200w, https://cdn-dfoll.nitrocdn.com/tSUsPcuDMaCDjkKGRxswpkeBalYirhyT/assets/images/optimized/rev-6b6fbab/www.fool.co.uk/wp-content/uploads/2023/06/ai-400x225.jpg 400w, https://cdn-dfoll.nitrocdn.com/tSUsPcuDMaCDjkKGRxswpkeBalYirhyT/assets/images/optimized/rev-6b6fbab/www.fool.co.uk/wp-content/uploads/2023/06/ai-663x373.jpg 663w, https://cdn-dfoll.nitrocdn.com/tSUsPcuDMaCDjkKGRxswpkeBalYirhyT/assets/images/optimized/rev-6b6fbab/www.fool.co.uk/wp-content/uploads/2023/06/ai-343x193.jpg 343w, ...

Image source: Getty Images October was not a great month for investors in AstraZeneca (LSE:AZN) following the release of disappointing ...

georgeclerk/iStock Unpublished via Getty Images The UK's National Institute for Clinical Excellence (NICE) in its final draft of the guideline ...